161 related articles for article (PubMed ID: 8879681)
21. Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82.
Senn HJ; Maibach R; Castiglione M; Jungi WF; Cavalli F; Leyvraz S; Obrecht JP; Schildknecht O; Siegenthaler P
J Clin Oncol; 1997 Jul; 15(7):2502-9. PubMed ID: 9215818
[TBL] [Abstract][Full Text] [Related]
22. Level of antithrombin III, protein C, protein S and other selected parameters of coagulation and fibrinolysis in the blood of the patients with recurrent deep venous thrombosis.
Swiatkiewicz A; Jurkowski P; Kotschy M; Ciecierski M; Jawień A
Med Sci Monit; 2002 Apr; 8(4):CR263-8. PubMed ID: 11951068
[TBL] [Abstract][Full Text] [Related]
23. Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients.
Ploner F; Jakesz R; Hausmaninger H; Kolb R; Stierer M; Fridrik M; Steindorfer P; Gnant M; Haider K; Mlineritsch B; Tschurtschenthaler G; Steger G; Seifert M; Kubista E; Samonigg H;
Onkologie; 2003 Apr; 26(2):115-9. PubMed ID: 12771518
[TBL] [Abstract][Full Text] [Related]
24. Impact of chemotherapy on thrombin generation and on the protein C pathway in breast cancer patients.
Mukherjee SD; Swystun LL; Mackman N; Wang JG; Pond G; Levine MN; Liaw PC
Pathophysiol Haemost Thromb; 2010; 37(2-4):88-97. PubMed ID: 21430357
[TBL] [Abstract][Full Text] [Related]
25. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
26. 3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study.
Ferreira Filho AF; Crown J; Cardoso F; Nogaret JM; Duffy K; Dolci S; Rowan S; O'Higgins N; Batter V; Paesmans M; Piccart MJ; Di Leo A
Anticancer Res; 2002; 22(4):2471-6. PubMed ID: 12174946
[TBL] [Abstract][Full Text] [Related]
27. Concurrent sequencing of full-dose CMF chemotherapy and radiation therapy in early breast cancer has no effect on treatment delivery.
Faul C; Brufsky A; Gerszten K; Flickinger J; Kunschner A; Jacob H; Vogel V
Eur J Cancer; 2003 Apr; 39(6):763-8. PubMed ID: 12651201
[TBL] [Abstract][Full Text] [Related]
28. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D;
J Clin Oncol; 2001 Feb; 19(4):943-53. PubMed ID: 11181656
[TBL] [Abstract][Full Text] [Related]
29. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
Watanabe T; Sano M; Takashima S; Kitaya T; Tokuda Y; Yoshimoto M; Kohno N; Nakagami K; Iwata H; Shimozuma K; Sonoo H; Tsuda H; Sakamoto G; Ohashi Y
J Clin Oncol; 2009 Mar; 27(9):1368-74. PubMed ID: 19204202
[TBL] [Abstract][Full Text] [Related]
30. [Serial changes in hemostatic and fibrinolytic states induced by coronary thrombolytic therapy].
Goto S; Handa S; Abe S; Takahashi E; Kawai Y; Watanabe K; Yoshikawa T; Hori S; Ikeda Y
J Cardiol; 1993; 23(4):335-41. PubMed ID: 8064582
[TBL] [Abstract][Full Text] [Related]
31. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
[TBL] [Abstract][Full Text] [Related]
32. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
Crivellari D; Bonetti M; Castiglione-Gertsch M; Gelber RD; Rudenstam CM; Thürlimann B; Price KN; Coates AS; Hürny C; Bernhard J; Lindtner J; Collins J; Senn HJ; Cavalli F; Forbes J; Gudgeon A; Simoncini E; Cortes-Funes H; Veronesi A; Fey M; Goldhirsch A
J Clin Oncol; 2000 Apr; 18(7):1412-22. PubMed ID: 10735888
[TBL] [Abstract][Full Text] [Related]
33. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma.
Schagen SB; van Dam FS; Muller MJ; Boogerd W; Lindeboom J; Bruning PF
Cancer; 1999 Feb; 85(3):640-50. PubMed ID: 10091737
[TBL] [Abstract][Full Text] [Related]
34. Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy.
de Azambuja E; Ameye L; Diaz M; Vandenbossche S; Aftimos P; Bejarano Hernández S; Shih-Li C; Delhaye F; Focan C; Cornez N; Vindevoghel A; Beauduin M; Lemort M; Paesmans M; Suter T; Piccart-Gebhart M
Eur J Cancer; 2015 Nov; 51(17):2517-24. PubMed ID: 26321502
[TBL] [Abstract][Full Text] [Related]
35. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
[TBL] [Abstract][Full Text] [Related]
36. Quality of adjuvant chemotherapy in primary breast cancer in a non-trial setting. A comprehensive cancer centre study. The Breast Cancer Group of the Dutch Comprehensive Cancer Centre East (IKO).
Ottevanger PB; Verhagen CA; Beex LV
Eur J Cancer; 1999 Mar; 35(3):386-91. PubMed ID: 10448287
[TBL] [Abstract][Full Text] [Related]
37. Combination chemotherapy for breast carcinoma using a combination of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) causes a platelet aggregation defect.
Kumar A; Chaturvedi P; Gupta YN
Int J Cancer; 1996 Apr; 66(2):159-61. PubMed ID: 8603804
[TBL] [Abstract][Full Text] [Related]
38. Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group.
Colleoni M; Price K; Castiglione-Gertsch M; Goldhirsch A; Coates A; Lindtner J; Collins J; Gelber RD; Thürlimann B; Rudenstam CM
Eur J Cancer; 1998 Oct; 34(11):1693-700. PubMed ID: 9893654
[TBL] [Abstract][Full Text] [Related]
39. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy.
Koppelmans V; Breteler MM; Boogerd W; Seynaeve C; Gundy C; Schagen SB
J Clin Oncol; 2012 Apr; 30(10):1080-6. PubMed ID: 22370315
[TBL] [Abstract][Full Text] [Related]
40. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients.
International Breast Cancer Study Group
J Clin Oncol; 1996 Jun; 14(6):1885-94. PubMed ID: 8656257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]